Reslizumab

Anaphylaxis

  • Anaphylaxis occurred with CINQAIR infusion in 0.3% of patients in placeb-controlled studies
  • Patients should be observed for an appropriate period of time after CINQAIR infusion; healthcare should be prepared to manage anaphylaxis that can be life-threatening
  • Discontinue CINQAIR immediately if the patient experiences anaphylaxis

Patient counseling

Package inserts

Keywords: Cinqair
Updated: April 2016